Drugs affecting plasma fibrinogen levels
- PMID: 1576094
- DOI: 10.1007/BF00050913
Drugs affecting plasma fibrinogen levels
Abstract
Current knowledge indicates that high plasma levels of fibrinogen help predict stroke and myocardial infarction. It is known that plasma fibrinogen is synthesized in the liver, that interleukin-6 (IL-6) affects this synthesis, and that, when exposed to appropriate stimuli, monocytes generate a variety of monokines, including IL-6. It is also known that prolonged administration of N-3 fatty acids, ticlopidine, fibrates, pentoxifylline, or alcohol lower plasma fibrinogen levels. The mechanism(s) involved in this effect are poorly understood. However, in view of the role of IL-6 and monocytes in the regulation of plasma fibrinogen levels, it is conceivable that the lowering effect of these drugs involves effects on some steps of the regulatory machinery. In addition to fibrinogen, IL-6 regulates the synthesis of other acute-phase proteins. This raises the question of whether high plasma fibrinogen levels do reflect the response of an acute-phase reactant to the severity of the atherosclerotic vascular damage taking place. Current evidence is inconclusive with respect to this possibility. On the other hand, the epidemiological data available indicate that measurements of plasma fibrinogen should be included in the cardiovascular risk-factor profile. In view of this, we believe that information emerging from population-based studies in which plasma fibrinogen is measured is important to identify appropriate directions to be followed to address unsolved issues in the area.
Similar articles
-
Drugs affecting plasma fibrinogen levels. Implications for new antithrombotic strategies.Prog Drug Res. 1996;46:169-81. doi: 10.1007/978-3-0348-8996-4_4. Prog Drug Res. 1996. PMID: 8754205 Review.
-
Genetic Modulation of Plasma Fibrinogen Concentrations: Possible Importance of Interleukin-6.J Thromb Thrombolysis. 1996;3(1):51-56. doi: 10.1007/BF00226411. J Thromb Thrombolysis. 1996. PMID: 10608037
-
Interleukin-6 as a central mediator of cardiovascular risk associated with chronic inflammation, smoking, diabetes, and visceral obesity: down-regulation with essential fatty acids, ethanol and pentoxifylline.Med Hypotheses. 1999 May;52(5):465-77. doi: 10.1054/mehy.1997.0684. Med Hypotheses. 1999. PMID: 10416955
-
Fibrinogen: its role in the hemostatic regulation in atherosclerosis.Semin Thromb Hemost. 1993;19(2):104-7. doi: 10.1055/s-2007-994012. Semin Thromb Hemost. 1993. PMID: 8356454 Review.
-
The effect of the interleukin-6 c/g-174 polymorphism and circulating interleukin-6 on fibrinogen plasma levels.Haematologica. 2001 Feb;86(2):199-204. Haematologica. 2001. PMID: 11224491
Cited by
-
Mesoglycan: clinical evidences for use in vascular diseases.Int J Vasc Med. 2010;2010:390643. doi: 10.1155/2010/390643. Epub 2010 Aug 31. Int J Vasc Med. 2010. PMID: 21152191 Free PMC article.
-
Effects of different antihypertensive drugs on plasma fibrinogen in hypertensive patients.Br J Clin Pharmacol. 1995 May;39(5):471-6. doi: 10.1111/j.1365-2125.1995.tb04482.x. Br J Clin Pharmacol. 1995. PMID: 7669481 Free PMC article. Clinical Trial.
-
Fenofibrate: a novel formulation (Triglide) in the treatment of lipid disorders: a review.Int J Nanomedicine. 2006;1(2):129-47. doi: 10.2147/nano.2006.1.2.129. Int J Nanomedicine. 2006. PMID: 17722529 Free PMC article. Review.
-
Acute retinal vein occlusion and cystic fibrosis.Int J Retina Vitreous. 2018 Jul 18;4:26. doi: 10.1186/s40942-018-0129-8. eCollection 2018. Int J Retina Vitreous. 2018. PMID: 30026964 Free PMC article.